Zepbound weight loss drug: Pharmaceutical company Eli Lilly predicts further jump in sales. Revenues are expected to rise to between $40.4 and $41.6 billion in 2024, the company announced on Tuesday.
That would be around a fifth more after sales climbed to $34.1 billion in 2023. The same active ingredient is in Lilly's weight loss product Zepbound, which has been available to significantly more people in the USA since November. Experts expect this to become the best-selling drug in the world.